Aaron Kantoff is a Venture Partner in the Medicxi investment team.
Prior to joining Medicxi, Aaron was a partner with Apple Tree Partners (ATP), where he was a key member of the life science investment team since 2011. While at ATP, he played a leading role in assembling several ATP portfolio companies, previously serving on the boards of Akero Therapeutics (NASDAQ: AKRO), Corvidia Therapeutics (acquired by Novo Nordisk), Elstar Therapeutics, Limelight Bio, and Syntimmune (acquired by Alexion). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics (NASDAQ: STOK) and led many of ATP's crossover and public biotech investments. Prior to joining ATP, Aaron held roles in private equity and investment banking.
Aaron received a BS in Finance and International Business from NYU Stern's School of Business. He also currently serves on the boards of two private biotech companies for which he was a founding board member, RayzeBio and Silagene.